Abstract: The vitreous may play an important role in the pathogenesis of various retinal disorders. Pharmacologic vitreolysis uses intravitreal pharmacologic agents to provide liquefaction of the vitreous and complete vitreoretinal separation. Ocriplasmin, a genetically engineered version of plasmin, has been shown in clinical trials to be able to safely release vitreomacular adhesion and close Stage 2 macular holes in a significant number of patients. Advancements in the development of this safe and effective method of vitreolysis have provided an alternative, nonsurgical treatment option to physicians who manage these patients. A roundtable of clinical investigators convened to discuss and summarize recent progress in pharmacologic vitreolysis. Preclinical studies, and efficacy and safety data from controlled clinical trials of ocriplasmin were presented and discussed. Case studies were then presented to provide an opportunity for experts to reveal their specific thoughts regarding ocriplasmin for the treatment of vitreomacular adhesion and resulting vitreomacular traction and macular holes, based on their own interpretation of current clinical data and experience.
Retina Service at the Gavin Herbert Eye Institute, Department of Ophthalmology, University of California, Irvine, California.
Reprint Requests: Baruch Kuppermann, MD, PhD, Retina Service at the Gavin Herbert Eye Institute, Department of Ophthalmology, University of California, Irvine, California; e-mail: email@example.com
Financial Disclosure: Clinical Research Support: Alimera, Allergan, Genentech, GlaxoSmithKline, Regeneron, ThromboGenics. Dr. Kuppermann is a consultant for Alimera, Allegro, Allergan, Fovea, Genentech, Glaukos, Neovista, Novagali, Novartis, Ophthotech, Pfizer, Regeneron, ThromboGenics.